These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38258439)

  • 1. Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents.
    Khatun S; Amin SA; Choudhury D; Chowdhury B; Jha T; Gayen S
    Expert Opin Drug Discov; 2024 Mar; 19(3):353-368. PubMed ID: 38258439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoform-Selective Versus Nonselective Histone Deacetylase Inhibitors in HIV Latency Reversal.
    Boateng AT; Abaidoo-Myles A; Bonney EY; Kyei GB
    AIDS Res Hum Retroviruses; 2022 Aug; 38(8):615-621. PubMed ID: 35778852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cells.
    Peterson JJ; Lewis CA; Burgos SD; Manickam A; Xu Y; Rowley AA; Clutton G; Richardson B; Zou F; Simon JM; Margolis DM; Goonetilleke N; Browne EP
    Cell Chem Biol; 2023 Dec; 30(12):1617-1633.e9. PubMed ID: 38134881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency.
    Schonhofer C; Yi J; Sciorillo A; Andrae-Marobela K; Cochrane A; Harris M; Brumme ZL; Brockman MA; Mounzer K; Hart C; Gyampoh K; Yuan Z; Montaner LJ; Tietjen I
    Biochem Pharmacol; 2021 Apr; 186():114462. PubMed ID: 33577894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells.
    Kobayashi Y; Gélinas C; Dougherty JP
    J Gen Virol; 2017 Apr; 98(4):799-809. PubMed ID: 28113052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells.
    Huber K; Doyon G; Plaks J; Fyne E; Mellors JW; Sluis-Cremer N
    J Biol Chem; 2011 Jun; 286(25):22211-8. PubMed ID: 21531716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of IL-15 and latency reversing agent combinations in the reactivation and NK cell-mediated suppression of the HIV reservoir.
    Covino DA; Desimio MG; Doria M
    Sci Rep; 2022 Nov; 12(1):18567. PubMed ID: 36329160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
    Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
    Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
    Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective HDAC inhibition for the disruption of latent HIV-1 infection.
    Barton KM; Archin NM; Keedy KS; Espeseth AS; Zhang YL; Gale J; Wagner FF; Holson EB; Margolis DM
    PLoS One; 2014; 9(8):e102684. PubMed ID: 25136952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of latent HIV by histone deacetylase inhibitors.
    Shirakawa K; Chavez L; Hakre S; Calvanese V; Verdin E
    Trends Microbiol; 2013 Jun; 21(6):277-85. PubMed ID: 23517573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors.
    Archin NM; Keedy KS; Espeseth A; Dang H; Hazuda DJ; Margolis DM
    AIDS; 2009 Sep; 23(14):1799-806. PubMed ID: 19590405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosome-Mediated Delivery Of Hdac Inhibitors and Oxygen Molecules for the Transcriptional Reactivation of Latent Hiv-Infected Cd4
    Hong J; Choi Y; Lee G; Kim J; Jang Y; Yoon CH; Seo HW; Park IK; Kang SH; Choi J
    Small; 2023 Sep; 19(37):e2301730. PubMed ID: 37118849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
    Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
    PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.